58.43  -0.59 (-1%)		07-31 16:00
Open: 58.795 High: 59.1173 Volume: 2,151,546		Pre. Close: 59.02 Low: 58.26 Market Cap: 25,132(M)

Short term
Mid term
Targets	6-month :	70.59	1-year :	82.45
Resists	First :	60.43	Second :	70.59
Pivot price	58.18
Supports	First :	56.83	Second :	54.59
MAs	MA(5) :	59.06	MA(20) :	58.01
	MA(100) :	52.29	MA(250) :	44.06
MACD	MACD :	0.9	Signal :	0.9
%K %D	K(14,3) :	71.5	D(3) :	79.7
RSI	RSI(14): 55.1
52-week	High :	60.43	Low :	33.56

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ RPRX ] has closed below upper band by 44.7%. Bollinger Bands are 23.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	59.18 - 59.66	59.66 - 59.99
Low:	57.25 - 57.79	57.79 - 58.15
Close:	57.73 - 58.56	58.56 - 59.11

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Sat, 01 Aug 2026
Amundi Increases Stake in Royalty Pharma PLC $RPRX - MarketBeat

Fri, 31 Jul 2026
Vestor Capital LLC Acquires 71,688 Shares of Royalty Pharma PLC $RPRX - MarketBeat

Fri, 31 Jul 2026
Royalty Pharma PLC $RPRX Shares Sold by Empowered Funds LLC - MarketBeat

Thu, 30 Jul 2026
Royalty Pharma (RPRX) Could Be 40% Undervalued After Its Dividend Decision - finance.yahoo.com

Thu, 30 Jul 2026
Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat

Thu, 30 Jul 2026
Sei Investments Co. Sells 99,990 Shares of Royalty Pharma PLC $RPRX - MarketBeat

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Shares Out	443 (M)
Shares Float	414 (M)
Held by Insiders	6.5 (%)
Held by Institutions	86.2 (%)
Shares Short	12,130 (K)
Shares Short P.Month	11,130 (K)

EPS	1.89
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	15.52
Profit Margin	33.8 %
Operating Margin	100.3 %
Return on Assets (ttm)	5.5 %
Return on Equity (ttm)	13.7 %
Qtrly Rev. Growth	11 %
Gross Profit (p.s.)	6.33
Sales Per Share	5.5
EBITDA (p.s.)	0
Qtrly Earnings Growth	23.2 %
Operating Cash Flow	2,610 (M)
Levered Free Cash Flow	-980 (M)

PE Ratio	30.75
PEG Ratio	2.2
Price to Book value	3.76
Price to Sales	10.61
Price to Cash Flow	9.92

Dividend	0.23
Forward Dividend	0
Dividend Yield	0.3%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.